Clinical Trials Logo
  1. Home
  2. Metformin
  3. NCT03618472

Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells

Metformin Clinical Trial

Official title:
Effect of Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells : A Randomized Double Blind Placebo-controlled Trial

Clinical Trial Summary

Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in endometrial cancer cells.

Clinical Trial Description

Endometrial cancer is one of the most common gynecological cancers. Preclinical studies in endometrial cancer (EC) show that metformin reduces cellular proliferation by PI3K-AKT-mTOR inhibition. The investigators tested the hypothesis that short-term presurgical metformin reduces cellular proliferation in endometrial cancer. However, no good quality of evidence base supports the effectiveness of metformin for deceasing proliferative marker in endometrial cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03618472
Study type Interventional
Source Rajavithi Hospital
Contact
Status Completed
Phase N/A
Start date July 1, 2018
Completion date January 7, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Recruiting NCT05469659 - Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) Phase 2
Completed NCT00767351 - Variation in Serum Levels of Metformin in Patients With Reduced Renal Function
Recruiting NCT06126029 - Effect of Metformin as Add-on Therapy to Ibuprofen on Disease Activity in Knee Osteoarthritis Patients. Phase 2
Enrolling by invitation NCT05900284 - Safety and Feasibility of Metformin for Sepsis Induced AKI Phase 2
Enrolling by invitation NCT06125587 - Chiglitazar/Metformin in Non-obese Women With PCOS Phase 2/Phase 3
Not yet recruiting NCT05013112 - Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) N/A
Recruiting NCT03525028 - A Clinical Trial of Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis N/A
Recruiting NCT05680805 - Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS Phase 4
Not yet recruiting NCT05532813 - Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease) Phase 3
Recruiting NCT06325969 - PCOS Patients Immune Status Evaluation
Recruiting NCT06325956 - PCOS Immune Function Predicts Metformin Efficacy N/A
Completed NCT03335423 - Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions Phase 1
Recruiting NCT04477590 - Interactions of Medicine and Exercise With Meal Timing N/A
Not yet recruiting NCT06459310 - Pilot Study on Evaluating the Geroprotective Effect of Metformin Phase 2
Not yet recruiting NCT05412056 - Metformin to Prevent Preterm Birth in Twin Pregnancy Phase 2/Phase 3
Terminated NCT01756105 - Efficacy of Metformin in Achieving Glycaemia Goals as Recommended for the Treatment of Gestational Diabetes in Non Obese Women Phase 2
Completed NCT04377451 - Metformin in Dengue With Obesity Phase 1/Phase 2
Recruiting NCT04581447 - Extending Time Without Diabetes After Bariatric Surgery: a Trial Comparing the Metformin Addition or Not to Standard Care Phase 3
Not yet recruiting NCT05655728 - Treatment With Metformin in Chinese Children With Alport Syndrome Phase 4